Related references
Note: Only part of the references are listed.ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
Pertti J. Neuvonen et al.
CLINICAL PHARMACOKINETICS (2008)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans
Y. Yamasaki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
An improved and fully validated LC-MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma
Constantinos Apostolou et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Breast cancer resistance protein (ABCG2) and drug disposition:: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
Bradley L. Urquhart et al.
PHARMACOGENETICS AND GENOMICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2007)
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2
Ai Tamura et al.
CANCER SCIENCE (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Role of BCRP 421C>A polymorphism on rosuvastatin pharynacokinetics in healthy Chinese males
Wei Zhang et al.
CLINICA CHIMICA ACTA (2006)
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
Mikko Niemi et al.
PHARMACOGENETICS AND GENOMICS (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Mikko Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
Marja K. Pasanen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins
AE van Herwaarden et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats
KT Kivistö et al.
DRUG METABOLISM AND DISPOSITION (2005)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion- transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein
S Matsushima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Single nucleotide polymorphisms modify the transporter activity of ABCG2
K Morisaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment
CD Woodworth et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta
D Kobayashi et al.
DRUG METABOLISM AND DISPOSITION (2005)
Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
K Kajinami et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
S Mizuarai et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
KT Kivistö et al.
PHARMACOGENETICS (2004)
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
A Sparreboom et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Functional interaction of intestinal CYP3A4 and P-glycoprotein
KT Kivistö et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2004)
Pharmacogenetic study of statin therapy and cholesterol reduction
DI Chasman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Functional analysis of SNPs variants of BCRP/ABCG2
C Kondo et al.
PHARMACEUTICAL RESEARCH (2004)
Statin-associated myopathy
PD Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine
CP Zamber et al.
PHARMACOGENETICS (2003)
Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS
D Mulvana et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2000)
Share Paper
